Nowadays, clinical decision-making is focused on the assessment of hormone receptors (estrogen (ER) and progesterone (PR) receptors) and of the epidermal growth factor receptor (HER-2) status, by a combination of immunohistochemical and in situ hybridization techniques on tumor cells. Here, NR4A1 is linked to neoplasm.